DOES KNOWLEDGE OF ISLET CELL ANTIBODY STATUS HELP IN MANAGING DIABETES PRESENTING IN MIDDLE AND OLD-AGE

被引:4
作者
GREGORY, R
TATTERSALL, RB
机构
[1] Department of Diabetes, University Hospital, Nottingham
关键词
ISLET CELL ANTIBODY; LATE-ONSET DIABETES; TYPE-1; DIABETES;
D O I
10.1111/j.1464-5491.1991.tb01519.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It has been suggested that screening all patients with diabetes diagnosed in later life for islet cell antibodies (ICA) would help predict insulin dependence. We have surveyed the case notes of 55 patients (22 male; ages 37-88 years) who were found to be ICA positive over a 9-year screening period to assess what contribution knowledge of ICA status made to their management. Forty-two patients had been put on insulin (half within 6 months of diagnosis and the rest after up to 6 years). Of the 13 patients not on insulin, six were on diet alone and seven on oral hypoglycaemic agents after a median follow-up of 3 years. In 37 of the 42 patients, insulin treatment was started for clinical rather than immunological reasons (diabetic ketoacidosis, ketonuria, weight loss and/or severe symptoms). Five patients were started on insulin because of ICA status when there was no compelling reason on clinical grounds. Knowledge that seven non-insulin-treated patients were ICA positive made doctors reluctant to discharge them from clinic. The data suggest that routine ICA estimation in this age group is unnecessary, as the decision to treat with insulin is best made on clinical grounds, and ICA estimation can lead to unwarranted insulin treatment, or anxiety in patients and doctors who are aware of a positive result.
引用
收藏
页码:72 / 75
页数:4
相关论文
共 18 条
  • [1] Tattersall RB, Scott AR., When to use insulin in the maturity‐onset diabetic, Postgrad Med J, 63, pp. 859-864, (1987)
  • [2] Gale EAM, Dornan TL, Tattersall RB., Severely uncontrolled diabetes in the over‐50s, Diabetologia, 21, pp. 25-28, (1981)
  • [3] Groop LC, Pelkonen R., Koskimies S., Bottazzo GF, Doniach D., Secondary failure to treatment with oral anti‐diabetic agents in non‐insulin dependent diabetes, Diabetes Care, 9, pp. 129-133, (1986)
  • [4] Irvine WJ, Sawers JS, Feek, Prescott EJ, Duncan LJP., The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in diabetes mellitus, J Clin Lab Immunol, 2, pp. 23-26, (1979)
  • [5] di Mario U., Irvine WJ, Borsey DQ, Kyner JL, Weston J., Galfo C., Immune abnormalities in diabetic patients not requiring insulin at diagnosis, Diabetologia, 25, pp. 392-395, (1983)
  • [6] Lendrum R., Walker G., Cudworth AG, Theophanides C., Pyke D., Islet cell antibodies in diabetes mellitus, Lancet, 2, pp. 1273-1276, (1976)
  • [7] Pilcher C., Elliott RB., Improved sensitivity of islet cell cytoplasmic assay in diabetics (Letter), Lancet, 2, (1984)
  • [8] Johnson GD, Dorling J., Immunofluorescence and immunoperoxidase techniques, Techniques in Clinical Immunology, pp. 106-137, (1981)
  • [9] Irvine WJ, McCullum CJ, Gray RS, Et al., Pancreatic islet cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease and HLA type, Diabetes, 26, pp. 138-147, (1977)
  • [10] Lendrum R., Walker G., Cudworth AG, Et al., Islet cell antibodies in diabetes mellitus, Lancet, 2, pp. 1273-1276, (1976)